Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated parkinson’s disease

Abstract

Glucocerebrosidase 1 (GBA) mutations responsible for Gaucher disease (GD) are the most common genetic risk factor for Parkinson’s disease (PD). Although the genetic link between GD and PD is well established, the underlying molecular mechanism(s) are not well understood. We propose that glucosylsphingosine, a sphingolipid accumulating in GD, mediates PD pathology in GBA-associated PD. We show that, whereas GD-related sphingolipids (glucosykeramide, glucosylsphingosine, sphingosine, sphingosine-l-phosphate) promote a-synudein aggregation in vitro, glucosylsphingosine triggers the formation of oligomeric α-synuclein species capable of templating in human cells and neurons. Using newly generated GD/PD mouse lines of either sex [Gba mutant (N370S, L444P, KO) crossed to a-synuclein transgenics], we show that Gba mutations predispose to PD through a loss-of-function mechanism. We further demonstrate that glucosylsphingosine specifically accumulates in young GD/PD mouse brain. With age, brains exhibit glucosykeramide accumulations colocalized with a-synudein pathology. These findings indicate that glucosylsphingosine promotes pathological aggregation of a-synuclein, increasing PD risk in GD patients and carriers.